Conclusion
In conclusion, the lack of quantitative and comparative evidence assessing the impact of policies promoting price transparency is a clear call for further research. Collaborative pilots involving both national governments and researchers could help to align their interests and overcome the current inertia in evidence development. Additional evidence is needed to confirm the impact of a wide range of transparency measures on the management of medicine prices in countries all over the world. The evidence that is currently available, although from a single study, indicates that a national measure introducing price transparency along the supply chain may be effective in managing medicine prices.